Skip to main content
Erschienen in:

24.04.2017 | Nierenkarzinom | CME

Immuncheckpointinhibitoren

Neue therapeutische Behandlungsansätze in der Onkologie

verfasst von: Dr. med. Sebastian Scheich, Dr. med. Martin Sebastian

Erschienen in: Die Onkologie | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Immuncheckpointinhibitoren sind in verschiedenen Entitäten mittlerweile Therapiestandard. Beim malignen Melanom sind in der Erstlinie Pembrolizumab, Ipilimumab und Nivolumab sowie die Kombination aus Nivolumab und Ipilimumab zugelassen, außerdem Ipilimumab allein als adjuvante Therapie im Stadium III. Beim Lungenkarzinom ist Nivolumab für alle Histologien in der Zweitlinie und Pembrolizumab bei hoch PD-L1-positiven (PD-L1: „programmed cell death ligand 1“) Tumoren (> 50 %) in der Erstlinentherapie zugelassen. Beim Nierenzellkarzinom besteht die Zulassung von Nivolumab in der Zweitlinie, ebenso wie beim Hodgkin-Lymphom nach Versagen einer autologen Stammzelltransplantation und Brentuximab Vedotin. Beim Plattenepithelkarzinom des Kopf-Hals-Bereichs sind Pembrolizumab und Nivolumab in der Zweitlinie in den USA zugelassen, in Europa steht die Zulassung für Nivolumab kurz bevor. Für das Urothelkarzinom ist Atezolizumab in den USA in der Zweitlinie zugelassen. Wichtigste Nebenwirkungen sind „immune-related adverse events“.
Literatur
1.
Zurück zum Zitat Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205–214CrossRefPubMed Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205–214CrossRefPubMed
3.
Zurück zum Zitat Carter L, Fouser LA, Jussif J et al (2002) PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32(3):634–643CrossRefPubMed Carter L, Fouser LA, Jussif J et al (2002) PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32(3):634–643CrossRefPubMed
4.
Zurück zum Zitat Scheel AH, Dietel M, Heukamp LC et al (2016) Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29(10):1165–1172CrossRefPubMed Scheel AH, Dietel M, Heukamp LC et al (2016) Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29(10):1165–1172CrossRefPubMed
6.
Zurück zum Zitat Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723CrossRefPubMedPubMedCentral Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526CrossRefPubMed Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526CrossRefPubMed
9.
Zurück zum Zitat Eggermont AMM, Chiarion-Sileni V, Grob J‑J et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071). A randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522–530CrossRefPubMed Eggermont AMM, Chiarion-Sileni V, Grob J‑J et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071). A randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522–530CrossRefPubMed
10.
Zurück zum Zitat Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037). A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384CrossRefPubMed Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037). A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384CrossRefPubMed
11.
Zurück zum Zitat Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330CrossRefPubMed Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330CrossRefPubMed
12.
Zurück zum Zitat Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34CrossRefPubMed Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34CrossRefPubMed
13.
Zurück zum Zitat Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532CrossRefPubMed Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532CrossRefPubMed
14.
Zurück zum Zitat Ribas A, Hauschild A, Kefford R, Punt CJ, Haanen JB, Marmol M, Garbe C, Gomez-Navarro J, Pavlov D, Marshall M (2008) Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 26(15_suppl):LBA9011. doi:10.1200/jco.2008.26.15_suppl.lba9011 (abstract ASCO)CrossRef Ribas A, Hauschild A, Kefford R, Punt CJ, Haanen JB, Marmol M, Garbe C, Gomez-Navarro J, Pavlov D, Marshall M (2008) Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 26(15_suppl):LBA9011. doi:10.​1200/​jco.​2008.​26.​15_​suppl.​lba9011 (abstract ASCO)CrossRef
15.
Zurück zum Zitat Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813CrossRefPubMed Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813CrossRefPubMed
16.
Zurück zum Zitat Hammer HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Razak A, Pal SK, Voss M, Sharma P, Kollmannsberger CK, Heng D, Shen Y, Kurland J, Spratlin J, Gagnier P, Amin A (2015) Expanded cohort results from CheckMate 016: a hase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 33:abstr. 4516 Hammer HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Razak A, Pal SK, Voss M, Sharma P, Kollmannsberger CK, Heng D, Shen Y, Kurland J, Spratlin J, Gagnier P, Amin A (2015) Expanded cohort results from CheckMate 016: a hase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 33:abstr. 4516
17.
Zurück zum Zitat Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135CrossRefPubMedPubMedCentral Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639CrossRefPubMed Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639CrossRefPubMed
19.
Zurück zum Zitat Herbst RS, Baas P, Kim D‑W et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550CrossRefPubMed Herbst RS, Baas P, Kim D‑W et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550CrossRefPubMed
20.
Zurück zum Zitat Rittmeyer A, Barlesi F, Waterkamp D et al (2016) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK). A phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265. doi:10.1016/s0140-6736(16)32517-x CrossRefPubMed Rittmeyer A, Barlesi F, Waterkamp D et al (2016) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK). A phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265. doi:10.​1016/​s0140-6736(16)32517-x CrossRefPubMed
22.
Zurück zum Zitat Socinski M, Creelan B, Horn L et al (2016) A phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1) – positive NSCLC. Ann Oncol. doi:10.1093/annonc/mdw435.39 PubMedPubMedCentral Socinski M, Creelan B, Horn L et al (2016) A phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1) – positive NSCLC. Ann Oncol. doi:10.​1093/​annonc/​mdw435.​39 PubMedPubMedCentral
23.
Zurück zum Zitat Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy. A single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909–1920CrossRefPubMedPubMedCentral Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy. A single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909–1920CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Massard C, Gordon MS, Sharma S et al (2016) Safety and efficacy of Durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34(26):3119–3125CrossRefPubMed Massard C, Gordon MS, Sharma S et al (2016) Safety and efficacy of Durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34(26):3119–3125CrossRefPubMed
25.
Zurück zum Zitat Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin. A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17(9):1283–1294CrossRefPubMed Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin. A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17(9):1283–1294CrossRefPubMed
27.
Zurück zum Zitat Seiwert TY, Burtness B, Mehra R et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012). An open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965CrossRefPubMed Seiwert TY, Burtness B, Mehra R et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012). An open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965CrossRefPubMed
29.
Zurück zum Zitat Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148CrossRefPubMed Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148CrossRefPubMed
30.
Zurück zum Zitat Eigentler TK, Hassel JC, Berking C et al (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45:7–18CrossRefPubMed Eigentler TK, Hassel JC, Berking C et al (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45:7–18CrossRefPubMed
31.
Zurück zum Zitat Horvat TZ, Adel NG, Dang T‑O et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at memorial Sloan Kettering Cancer Center. J Clin Oncol 33(28):3193–3198CrossRefPubMedPubMedCentral Horvat TZ, Adel NG, Dang T‑O et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at memorial Sloan Kettering Cancer Center. J Clin Oncol 33(28):3193–3198CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420CrossRefPubMed Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420CrossRefPubMed
Metadaten
Titel
Immuncheckpointinhibitoren
Neue therapeutische Behandlungsansätze in der Onkologie
verfasst von
Dr. med. Sebastian Scheich
Dr. med. Martin Sebastian
Publikationsdatum
24.04.2017

Weitere Artikel der Ausgabe 7/2017

Der Onkologe 7/2017 Zur Ausgabe

Einführung zum Thema

Akute Leukämien

Palliativmedizin und Supportivtherapie

SOP – Schmerztherapie bei Palliativpatienten